Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 7/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108610 | 0.88 | CASP1 (0.38) | ALDH1A1CASP1MAPTKDM4ELMNA | |
| SCHEMBL20146220 | 0.88 | CASP1 (0.38) | ALDH1A1CASP1MAPTKDM4ELMNA | |
| SCHEMBL17108608 | 0.88 | CASP1 (0.38) | ALDH1A1CASP1MAPTKDM4ELMNA | |
| SCHEMBL17108619 | 0.76 | SYK (0.40) | ALDH1A1CASP1MAPTMEN1LMNA | |
| SCHEMBL18748453 | 0.73 | CASP1 (0.48) | ALDH1A1CASP1MAPT | |
| SCHEMBL17108605 | 0.71 | CTSA (0.44) | ALDH1A1MAPTKDM4ELMNAGAA | |
| SCHEMBL17101248 | 0.70 | HPGD (0.45) | ALDH1A1MAPTKDM4EMEN1LMNA | |
| SCHEMBL17108598 | 0.70 | SYK (0.42) | ALDH1A1MEN1LMNAMAPK1KMT2A | |
| SCHEMBL20146223 | 0.66 | ERN1 (0.47) | ALDH1A1CASP1MAPTMEN1KMT2A | |
| SCHEMBL17101442 | 0.63 | HPGD (0.50) | ALDH1A1MAPTKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | ALDH1A1 933/4885CASP1 3276/4885PTGER1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.